Understanding which gene mutations occur in your patient’s tumor and how they affect cancer-related cell signaling pathways to drive tumor growth provides the key to finding a suitable personalized therapy. More and more studies highlight the strong association between the genetic alterations of a patient’s tumor and the success of using tailored targeted therapies. These targeted therapies are already commonly used for some cancer types, such as for lung cancer, but are effective in a wide variety of cancer types.
ACT Genomics performs comprehensive genetic testing for your patient’s cancer. We analyze samples by next-generation sequencing with subsequent bioinformatics data processing and then utilize clinical databases to identify most promising matching tailored treatment options for your patients!
ACT Genomics provides pan-cancer panels and cancer-specific panels to serve patients with solid tumors. The panels designed for the analysis of important genes associated with targeted therapies are ACTDrug®+ and ACTOnco®+. We offer ACTMonitor™ and ACTBRCA™ to provide further information for treatment and cancer monitoring; the panel ACTRisk™ can identify individuals with an enhanced cancer risk and enable preventive actions.
With years of experience in Next Generation Sequencing (NGS) and clinical settings, we are capable of handling various specimens, including FFPE, frozen tissue, core needle biopsy, pleural effusion and ascites samples. With just a fraction of precious specimens, we can achieve an average sequencing depth of 1,000X to detect genetic alterations with high sensitivity. We are dedicated to deliver highly accurate results that cover all aspects of cancer, from diagnosis and treatment selection to disease monitoring. Our comprehensive report, including genomic alteration status, the biological function of mutated genes, our in-house curated cancer signaling pathways and therapeutic implications, covers the most relevant clinical evidence. It supports physicians to translate genomic information into a tailored treatment and to make the best therapeutic decision for their patients.
Identify high risk groups for hereditary cancer
Germline mutations in cancer-related genes occur in about 10 % of all cancer cases, revealing the importance of family cancer history and early cancer screening. The American Cancer Society (ACS) estimated that 20-30% of all colorectal cancers (CRCs) are familial, including two major types of inherited CRC, hereditary nonpolyposis colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP). The American Society of Clinical Oncology (ASCO) reported that BRCA mutation carriers have an increased risk of developing breast cancer (54-85%), ovarian cancer (40-60%), and prostate cancer (20%).
Your cancer patients may have inherited mutations in cancer-related genes, and their family members may therefore have higher risk of developing cancer. It is recommended for family members of patients with such mutations to use hereditary genetic testing to assess their hereditary cancer risk, and to follow-up regularly to prevent cancer as early as possible.
If you would like to identify high risk groups for hereditary cancer, you may consider using our risk assessment service: ACTRisk™
Identify more evidence-based treatment options
We have different genomic profiling services which can satisfy individual patients’ needs. Using genetic testing before cancer treatment can help you to develop a better treatment strategies for your patients. To understand which therapy bests suits your patient, it is important to understand the mechanism driving the growth of your patient’s tumor. Since 300 to 400 genes in different cancer signaling pathways may be involved in this process, comprehensive genomic profiling services are required for thorough analysis. ACTOnco®+ is a comprehensive tumor genomic profiling service that covers more than 400 cancer-related genes to uncover the cancer mechanism of your patient and find the most appropriate matching targeted therapy based on a whole pathway analysis.
ACTDrug®+ is a tumor genetic test that precisely analyses carefully selected cancer-related genes with well-defined therapeutic implications, especially for patients with breast, lung and colorectal cancer.
ACTBRCA ™ detects germline and somatic mutations in the BRCA1/2 genes. The test is therefore capable to identify patients with breast, ovarian, prostate and pancreatic cancer that may benefit from targeted therapy by PARP inhibitors and informs about an inherited risk for developing those specific cancers.
If you would like to have a comprehensive evaluation of chemotherapy and targeted therapy choices for your patient, you may consider using our comprehensive genomic profiling service: ACTOnco®+.
If you would like to have an evaluation of targeted therapy choices for your patient, you may consider using our targeted genomic profiling service: ACTDrug ®+
If you would like to have an evaluation for specific drug choices for your patient, you may consider using our BRCA1/2 analyzing panel, ACTBRCA™
Monitor treatment efficiency using liquid biopsy
Monitoring tumor relapse and therapy success by imaging methods or traditional cancer biomarkers such as CEA only allow a delayed assessment of tumor development. These tests are less accurate than liquid biopsy tests that detect circulating tumor DNA (ctDNA) in the blood. ACTMonitor™ detects changes in the levels of ctDNA fast and accurately and therefore allows a real-time monitoring of changes in tumor burden. The test informs you about therapy success, resistance and tumor relapse very early and enables you to make faster adaptions of your patient’s treatment. If you would like to monitor treatment more effectively for your patient, you may consider using our ctDNA detection service, ACTMonitor ™
Predict Immunotherapy Response
Cancer immunotherapy can have impressive long-lasting effects, but not all patients are likely to benefit from this costly treatment. Patients treated with checkpoint inhibitors respond better to immunotherapy if their tumors harbor high mutation burden.
ACTOnco™ helps you to evaluate the patient- specific tumor mutation burden and to predict if your patient is likely to benefit from using immunotherapy with checkpoint inhibitors.
If you would like to predict if you are suitable for immunotherapy, you may consider using our immunotherapy response prediction service, ACTOnco ™
A new ERK1/2 inhibitor showed clinical activity in patients with NRAS and BRAF-mutant solid tumors. 2018-03-31
In a multicenter phase I trial (NCT01781429), patients with NRAS, BRAF or MEK-mutated advanced solid tumor were treated with ulixertinib, an ERK1/2 inhibitor, to identify its safeness and clinical activity. The results demonstrated that ulixertinib was we
Cases on genetic information-guided treatment in patients with less common ERBB2 mutations 2018-03-31
The authors report two cases with the less common ERBB2 transmembrane domain (TMD) mutation. They were treated with afatinib and were confirmed achieving clinical benefits. There are other cases with the less common ERBB2 mutation as reported in The Cance
ctDNA could predict the treatment response of palbociclib and fulvestrant for breast cancer patients 2018-03-31
In a phase III (PALOMA-3) study, clinical activity of palbociclib plus fulvestrant was confirmed in advanced hormone receptor-positive, HER2-negative breast cancer patients whose tumor had previously progressed on endocrine treatment. In this study, the a
New data from a phase IIa trial revealed the potential of the targeted therapy across tumor types on the basis of molecular profiles 2018-03-31
In the phase IIa (MyPathway) study, the patients with different advanced solid tumors harboring Her2, BRAF, EGFR or Hedgehog pathway alterations were treated with matching but are outside labeling targeted therapy. The results evaluated the efficacy of th
Early-onset hereditary ovarian cancer may be an X-linked model 2018-03-31
From 892 grandmother-granddaughter pairs of familial ovarian cancer samples, researchers found that the early-onset hereditary ovarian cancer gene may be located near the MAGEC3 gene on the X chromosome, and the male relatives with this mutation also have
Erdafitinib may show clinical activity in urothelial cancer with FGFR alterations 2018-03-01
Based on the results of a phase II trial, erdafitinib, a pan-FGFR inhibitor, exhibited response in urothelial cancer patients who have progressed after standard chemotherapy with FGFR alterations.
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
